APOE and Alzheimer disease: Despite the recent licensing of lecanemab as the first ever AD-modifying drug approved in the UK (excluding Northern Ireland) by the Medicines and Healthcare Products Regulatory Agency (MHRA) for individuals with early AD (except for APOE ε4 allele homozygotes), the drug’s appraisal by NICE was unfavourable.13 This decision was attributed to the cost of providing the drug, including fortnightly drug infusions and intensive monitoring for side-effects in combination with the relatively small cognitive benefits.